Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...

The stock's fall snapped a three-day winning streak.

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

This week's dividend activity included increased payouts from Gilead Sciences (GILD) and Meta Platforms (NASDAQ:META) as well as declarations from companies such as Nike (NYSE:NKE) and Unilever (UL).

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

US equity indexes rose this week as investors weighed the Trump administration's global punitive tariffs policy, and Federal Reserve Chair Jerome Powell reiterated there's no hurry to lower interest ...

The Chargers hosted the Palisades High School football program at The Bolt. Upon arrival, the Pali High student-athletes all received Chargers practice gear and headed to the weight room for an ...

It is vital for sponsors to reduce the burden on the site if they also want to lessen the strain on patients, said Shantheri Pai, associate director clinical operations for oncology at Gilead while ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.